Today: 17 May 2026
Woolworths shares slip as rate-hike talk dents “defensives”; RBA decision looms
4 March 2026
1 min read

Woolworths shares slip as rate-hike talk dents “defensives”; RBA decision looms

Sydney, March 4, 2026, 17:22 (AEDT) — Trading wraps for the day. After-hours.

  • Woolworths slipped 1.0% to A$36.00, mirroring a subdued session across Australia.
  • Investors are reworking interest-rate bets after the RBA called a March hike “live.” Reuters
  • All eyes now shift to the Reserve Bank of Australia, with its next policy decision set for March 17, following the March 16–17 meeting.

Woolworths Group Ltd slipped Wednesday, with investors cutting back on defensive consumer stocks as bets increased that the Reserve Bank of Australia might hike rates again this month.

The shares slipped 0.35 Australian dollars, landing at A$36.00—a drop of roughly 1.0%.

This shift is grabbing attention, as higher rates often sap demand for supermarket stocks—the go-to for investors chasing stable earnings when markets get rough. The RBA this week signaled every meeting is “live,” and it isn’t ruling out a rate hike in March if inflation picks up. Reuters

Jitters over rates remain tightly linked to volatile energy costs and the unpredictable ways inflation seeps through, putting extra strain on consumers at the register—even though grocery retailers are faring better than most cyclicals.

Shares in Woolworths have hovered close to their recent peaks since the company’s half-year results in late February. The retailer highlighted stronger momentum in its Australian Food unit and bumped up its interim dividend, but also disclosed significant remediation costs linked to staff underpayments.

Woolworths and rival Coles often trade in step with bond yields, especially when investors zero in on capital costs instead of the usual pricing skirmishes. A drop on Wednesday kept both names under the spotlight, with investors shuffling between defensives and banks as they parse the latest signals on rates.

With Woolworths, the focus now turns to whether families pull back spending if rates jump again, and just how fast suppliers will pass any fresh input cost hikes onto shoppers given inflation’s persistence.

But if rate expectations keep climbing, that standard “defensive” strategy might not hold up—valuation support can vanish quickly. Any wobble in volumes or a pick-up in promotions could make the downside a lot steeper. Reuters

Eyes shift to the RBA’s Monetary Policy Board gathering set for March 16–17, with a rate decision landing on March 17. That’s shaping up as the next clear driver for Australian equities, with day-to-day positions riding on the rate outlook.

Stock Market Today

  • Monster Beverage (MNST) Stock Near Fair Value After Multi-Year Gains
    May 16, 2026, 9:18 PM EDT. Monster Beverage (MNST) has delivered strong returns, rising nearly 89% over five years. The stock recently traded at around $87, modestly above its estimated intrinsic value of $80.02 based on a Discounted Cash Flow (DCF) model. This valuation approach projects Monster's free cash flow growing from $1.94 billion to over $3 billion by 2030. Despite impressive share price gains, the DCF suggests Monster is roughly 8.8% overvalued, indicating current prices are close to fair value rather than significantly overpriced. While the company's position in the US energy drink market supports growth prospects, its valuation score was 0 out of 6 on standard metrics, urging caution for new investors. Traders should monitor valuation shifts and market developments to time entries appropriately.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz
Previous Story

Stock Market Today 04.03.2026

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform
Next Story

Snowflake edges closer to the sales floor as EY and Canva roll out “agentic” AI platform

Go toTop